Clinical trial participation among underserved communities: Insights from the Louisiana Community Engagement Alliance.
| Autor: | Craig LS; Tulane University, School of Medicine, New Orleans, LA, USA., Sarpong DF; Xavier University of Louisiana, College of Pharmacy, New Orleans, LA, USA; Yale School of Medicine, General Internal Medicine, Office of Health Equity Research., Peacock EM; Tulane University, School of Medicine, New Orleans, LA, USA., Theall KP; Tulane University, School of Public Health and Tropical Medicine, New Orleans, LA, USA., Williams L; Xavier University of Louisiana, College of Pharmacy, New Orleans, LA, USA., Al-Dahir S; Xavier University of Louisiana, College of Pharmacy, New Orleans, LA, USA., Davis TC; Louisiana State University Health Shreveport, Shreveport, LA, USA., Arnold CL; Louisiana State University Health Shreveport, Shreveport, LA, USA., Williams A; Tulane University, School of Public Health and Tropical Medicine, New Orleans, LA, USA., Fields T; Xavier University of Louisiana, College of Pharmacy, New Orleans, LA, USA., Wilson M; Tulane University, School of Medicine, New Orleans, LA, USA., Krousel-Wood M; Tulane University, School of Medicine, New Orleans, LA, USA; Tulane University, School of Public Health and Tropical Medicine, New Orleans, LA, USA. Electronic address: mawood@tulane.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The American journal of the medical sciences [Am J Med Sci] 2023 Oct; Vol. 366 (4), pp. 254-262. Date of Electronic Publication: 2023 Jul 28. |
| DOI: | 10.1016/j.amjms.2023.07.011 |
| Abstrakt: | Background: Diverse, equitable and inclusive participation in clinical research is needed to ensure evidence-based clinical practice and lessen disparities in health outcomes. Yet, clinical trial participation remains critically low in minoritized communities, particularly among Blacks. The Louisiana Community Engagement Alliance against COVID-19 Disparities (LA-CEAL) was launched in response to the disproportionate impact of COVID-19 on Black Louisianans to understand community barriers and preferences and increase inclusive participation in research. This study aims to understand perceptions regarding COVID-19 trial participation among underrepresented Louisianans. Methods: A rapid assessment integrating cross-sectional, surveys among federally qualified health center (FQHC) patients and community residents, and focus group discussions (FGDs) from community representatives was conducted in 2020-2021. Factors and perceptions underlying trial participation were identified using logistic regression models and thematic analyses, respectively. Results: Quantitative findings (FQHC: N=908, mean age=46.6 years, 66.4% Black; community: N=504, mean age=54.2 years, 93.7% Black) indicated that 0.9% and 3.6%, respectively, ever participated in a COVID-19 trial. Doctors/Healthcare providers were most trusted (FQHC=55.1%; community=59.3%) sources of information about trials. Advancing age was associated with increased odds of being very willing to participate (OR Conclusion: COVID-19 trial participation rates were low in our sample. Altruism was a key facilitator to participation; fear, mistrust, and low awareness were predominant barriers. Community-centered approaches, engaging informed providers and trusted community members, may facilitate inclusive trial participation. Competing Interests: Declaration of Competing Interest The authors have no conflicts of interest to disclose. (Copyright © 2023. Published by Elsevier Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|